Cargando…

Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults

LHF-535 is a small-molecule antiviral currently under development as a therapeutic option to treat Lassa fever and other viral hemorrhagic fevers of arenavirus origin. The human safety and pharmacokinetics of LHF-535 were evaluated in two phase 1 trials in healthy volunteers. The first study was a d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amberg, Sean M., Snyder, Benjamin, Vliet-Gregg, Portia A., Tarcha, Eric J., Posakony, Jeff, Bedard, Kristin M., Heald, Alison E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2022
Materias:	Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664847/ https://www.ncbi.nlm.nih.gov/pubmed/36314868 http://dx.doi.org/10.1128/aac.00951-22

Ejemplares similares

Lassa antiviral LHF-535 protects guinea pigs from lethal challenge
por: Cashman, Kathleen A., et al.
Publicado: (2022)

Screening of Botanical Drugs against Lassa Virus Entry
por: Liu, Yang, et al.
Publicado: (2021)

Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
por: McMillan, JoEllyn, et al.
Publicado: (2017)

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
por: Ford, S. L., et al.
Publicado: (2017)

Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021)

Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir
por: Borrego, Belén, et al.
Publicado: (2019)

Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library
por: Wang, Peilin, et al.
Publicado: (2018)

Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi
por: Dickinson, Laura, et al.
Publicado: (2014)

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men
por: Han, Kelong, et al.
Publicado: (2022)

Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis
por: Lingscheid, Tilman, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) Investigational Product (COVID-HIGIV) in Healthy Adults: a Randomized, Controlled, Double-Blinded, Phase 1 Study
por: Liu, Sean T. H., et al.
Publicado: (2023)

Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing
por: Innes, Steve, et al.
Publicado: (2018)

Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years
por: Luo, Man, et al.
Publicado: (2016)

Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
por: Vaddady, Pavan, et al.
Publicado: (2020)

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers
por: Kankam, Martin K., et al.
Publicado: (2021)

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis
por: Berliba, Elina, et al.
Publicado: (2019)

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
por: Griffin, M. Pamela, et al.
Publicado: (2017)

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
por: Painter, Wendy P., et al.
Publicado: (2021)

Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region
por: Han, Kelong, et al.
Publicado: (2022)

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein
por: DeVincenzo, John, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
por: Shimizu, Ryosuke, et al.
Publicado: (2022)

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study
por: Steens, Jean-Marc, et al.
Publicado: (2017)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study
por: Li, Yinjuan, et al.
Publicado: (2021)

TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
por: Bam, Rujuta A., et al.
Publicado: (2016)

Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses
por: Ekins, Sean, et al.
Publicado: (2020)

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
por: Tsiang, Manuel, et al.
Publicado: (2016)

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection
por: Mehta, Rashmi, et al.
Publicado: (2018)

Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
por: Zumbrun, Elizabeth E., et al.
Publicado: (2022)

Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation
por: Maertens, Johan, et al.
Publicado: (2020)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
por: Dieterich, Douglas, et al.
Publicado: (2014)

Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
por: Krishnan, Preethi, et al.
Publicado: (2015)

Influenza A(H7N9) Virus Acquires Resistance-Related Neuraminidase I222T Substitution When Infected Mallards Are Exposed to Low Levels of Oseltamivir in Water
por: Gillman, Anna, et al.
Publicado: (2015)

Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection
por: Lawitz, Eric J., et al.
Publicado: (2016)

Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus
por: Levendosky, Keith, et al.
Publicado: (2015)

Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model
por: Farooqui, Amber, et al.
Publicado: (2015)

Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C
por: Ulferts, Rachel, et al.
Publicado: (2016)

Multipurpose Prevention Approaches with Antiretroviral-Based Formulations
por: Jean-Pierre, Ninochka, et al.
Publicado: (2016)

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir
por: Krishnan, Preethi, et al.
Publicado: (2016)

Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus
por: Feng, Joy Y., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_knlf32mcomac2gck7il9l7e8g7